Podcasts about Roar

They offer a quieter ride with far less pollution. Learn more at https://www.yaleclimateconnections.org/ 

FAN MAIL--We would love YOUR feedback--Send us a Text MessageWhen the numbers are this strong—near four percent growth across three straight quarters, inflation easing, wages outpacing prices—it's tempting for Washington to claim credit and start tinkering. We make a different case: the smartest move is restraint. Let a running economy keep its stride by preserving the incentives that sparked it—lower taxes, lighter regulatory loads, abundant energy, and clear rules that reward productivity.We revisit the value of aiming high, channeling the moonshot mindset into a push for sustained growth. That ambition isn't about bluster; it's about setting policies that shift risk-reward in favor of investing, hiring, and building. From streamlined regulation to pro-energy approaches that cut costs across supply chains, we connect today's momentum to classic supply-side principles. The results show up in real wages beating inflation, record-breaking markets, lower gas prices, and even a narrowing deficit tied to trade policy shifts.Then we pressure-test the latest panic proposals: price controls on credit cards that would shrink access and hide costs, fifty-year mortgages that trap families in interest, new lifelines for the housing GSEs that risk replaying old crises, bans on investors that choke housing supply, and government equity stakes that politicize innovation. These aren't growth strategies—they're distractions that could derail compounding progress. Our message to policymakers is simple and urgent: don't blink. Hold the line, keep the rules clear, and let the economy run.If you're aligned with growth you can feel, share this episode with a friend, hit follow, and leave a quick review to help more listeners find the show.Key Points from the Episode:• opening quote framing growth-first priorities• aiming high on GDP growth and why it matters• evidence of momentum in growth, inflation, wages, and markets• critique of price controls, ultra-long mortgages, and housing meddling• reminder of supply-side foundations and proven results• call to hold steady: don't blink, let it runBe sure to check out our show page at teammojoacademy.com, where we have everything we discussed in this podcast as well as other great resourcesOther resources: Want to leave a review? Click here, and if we earned a five-star review from you **high five and knuckle bumps**, we appreciate it greatly!

In this conversation, we're wrestling through identity, purpose, and belonging in a way that keeps bringing us back to one core truth: our identity is not rooted in what we do, what we've built, or what we've achieved. Our identity is rooted in who we are in Christ, and who we are with Him. We're reminded that obedience is not an add-on to faith; it's the evidence of it. And the more we abide in Jesus, the more we recognize that purpose is not something we manufacture; it's something we discover in relationship. We don't find clarity by striving harder. We find clarity by staying close. As we examine Scripture, we see this pattern repeated again and again: identity precedes assignment. God doesn't hand people a calling first and hope they figure out who they are later. He establishes belonging, then He entrusts responsibility. When we understand that we belong to God, it reshapes how we make decisions, what we say yes to, and what we can finally release. Our "why" gets purified. Our motives get exposed. Our pace changes. Our ambition gets reordered under His Lordship. Ultimately, this conversation is our call back to the center: a deeper relationship with Jesus. Not using Him to fuel our goals, but yielding our goals to His leadership. Because when Jesus is Lord, we don't have to chase identity. We live from it. If you want to go deeper with me, join the waitlist for my newest offer for Christian writers and authors: • 7 minutes a day • 7 days • 7 trainings • The old way of selling books is dead. • Learn the framework for repeatable book sales beyond Amazon. Join here If you enjoyed this episode, please share it with someone you think it will encourage and uplift. And be sure to follow me on Instagram at Resist and Roar for more faith-filled business leadership, plus support for writers and Christian authors who want consistent book sales. I'd love to hear from you. Feel free to DM me your thoughts on the podcast, or send over your prayer requests.

Recorded live in Glendale, CA, this story with roots in India and Vietnam follows a trio of birds on an illuminating adventure to bring back to the sun. Sign up for our monthly newsletter, "The Lion's Roar", here.

This week, it’s all about implementation. After weeks of exploring community, culture, values, and visibility, Stacey brings everything together with a simple challenge: what’s the one thing you’re actually going to do? In this wrap-up episode of the Turning Culture Into Capital series, Stacey shares three practical, powerful steps you can take right now to bring your culture to life and make a real impact—without feeling overwhelmed. You’ll learn: ✨ How to define your mission, vision, and values—and why they matter✨ How to create action statements that guide hiring, leadership, and decision-making✨ The difference between visibility and impact—and how to choose a strategy that suits your current season✨ Why you don’t need a big budget (or a full team) to make a big difference✨ How to delegate, get creative, and take just one small step towards community connection Plus, Stacey shares real examples from her own early business journey (hello, sausage sizzles and walking laps while pregnant!)—reminding us that what matters most is starting where you are.

CINCINNATI -- The Super Bowl LX matchup is set for Santa Clara and it's a rematch of Super Bowl XLIX 11 years ago as the New England Patriots play in the big game for a record-12th time while Seattle is appearing in its fourth. In the last game, Malcolm Butler intercepted Russell Wilson in the closing moments to help seal Tom Brady's fourth Super Bowl title. What can the Bengals take from the way the two teams are built? Looking ahead three months, what should the Bengals be targeting at No. 10 in the draft? Trags and Skinny are back to discuss it all. Learn more about your ad choices. Visit megaphone.fm/adchoices

There are 15 days until Detroit Tigers pitchers and catchers report to spring training in Lakeland, Florida. On "Days of Roar," Evan Petzold and Chris Brown react to the Tigers signing outfielder Corey Julks to a minor-league contract, evaluating if Julks could unseat Jahmai Jones as the right-handed-hitting outfielder who thrives against left-handed pitching. Evan and Chris debate whether targeting mid-tier starting pitchers in free agency is the best strategy for the Tigers — and who belongs on that list beyond Chris Bassitt, then Chris takes a deep dive into the Tigers' four consensus top-100 prospects: Kevin McGonigle, Max Clark, Bryce Rainer and Josue Briceño, plus who might be the next prospect from the Tigers to join them. Former Tigers catcher/third baseman Brandon Inge joins the show for a 30-minute interview, discussing the opening of his Inge Performance Lab, the Hall of Fame electees (Carlos Beltrán and Andruw Jones) and memories from his Tigers career. Evan and Chris also take a listener question about when McGonigle and Clark could join the Tigers for their MLB debuts. Follow Evan on X/Twitter here. Read Evan's most recent work here

Dustin Fox joins the podcast to preview the Australian Open quarterfinal round, which features four American women and all the top seeds in both draws. Fox analyzes Carlos Alcaraz's greatness, Jannik Sinner's form after surviving the heat, and the level that Ben Shelton and Learner Tien are bringing in Melbourne. The former NFL player and tennis enthusiast also weighs in on Novak Djokovic's chances for another grand slam, and whether young American Iva Jovic can challenge Aryna Sabalenka. Fox also dives into Coco Gauff's chances, and looks at some dynamic women's matches that include Jessica Pegula vs Amanda Anisimova and Iga Swiatek vs. Coco Gauff. Hosted by Mitch Michals. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Maddie Bowen the new owner of Lions Roar Brewing in Westfield, NJ Joins me for 2 segments. News from Wynkoop, Firestone Walker, Big Brew, NYC Brewed, Funky Buddha. A recap of Dogfish Head's 30 min pop up in NYC. My review of Emberside Brewing tap takeover. NJ ABC actually listened to brewers, legislators and the general public and more. @njcraftbeer @hoppedupnetwork #drinklocal #smallbusinessowners #music #podcastsSee omnystudio.com/listener for privacy information.

ICE flights out of Wayne County airports spark concern 2026 tax season: No tax on overtime, senior deduction, confusing rules Days of Roar: Tarik Skubal vs. Detroit Tigers: Who wins arbitration showdown? Evan Drellich on MLB labor, business issues Subscribe/follow, rate and share "Days of Roar” available on all podcast platforms including: Apple Podcasts Spotify Amazon Music YouTube

We're back from our longest hiatus ever - sorry about that. Holidays, birthdays, being first time parents, and the death of a beloved pet kept Joey playing the role of a podcast-cancelling fool every week, and we really appreciate your patience! Guts battles an elephant-whale like sea beast, succumbs to the Berserker Armor AGAIN (big surprise) and the crew enter the most bustling city ever as the entirety of Midland prepares for war with the Kushan. Enjoy! Follow No Guts, No Glory on Instagram: https://www.instagram.com/nogutsnoglorypc/ Check out Joey and Ryan's Renaissance Martial Arts organization: https://www.thearma.org/ Check out Steve and Joey's other podcast: https://podcasts.apple.com/us/podcast/probing-ancient-aliens/id1321801647 https://open.spotify.com/show/3aREEXpe4DE37LsNkUxntW Check out Steve and Joey's Patreon for that other podcast: https://www.patreon.com/probingancientaliens

Dating someone with covert narcissistic traits rarely feels abusive at first. In fact, it often feels intoxicating—intense attention, deep emotional connection, and a sense of being chosen in a way you may never have experienced before. This episode explores why that intensity feels so powerful—and why it so often turns confusing, controlling, and unsafe. In this deeply honest conversation, Jacquie Roar shares her personal story of navigating covert narcissism in a dating relationship. She talks openly about love bombing, emotional manipulation, isolation, and how her sense of self slowly eroded long before she had words for what was happening. Like many survivors, she believed the problem was something she could fix—if only she tried harder, loved better, or showed more understanding. Together, we explore how covert narcissistic abuse impacts the nervous system, why leaving can feel harder than staying, and why the aftermath often includes depression, grief, and intense self-doubt rather than immediate relief. Jacquie also speaks about the moment that changed everything—when survival became more important than hope—and how healing required learning to accept healthy love after chaos. This episode is for anyone who has ever questioned themselves after a relationship ended and wondered: Why did it feel so good at first? Why did I get smaller over time? Why did peace feel unfamiliar after I left? You are not weak. You were responding to a dynamic designed to confuse, bond, and control. This conversation offers clarity, validation, and hope—without pressure, judgment, or diagnosis. Chapters 00:00 Introduction and Guest Introduction 02:56 Jacquie's Background and Music Career 04:39 Understanding Narcissism and Red Flags 10:07 Recognizing Emotional Abuse 17:22 Self-Care and Healing Journey 25:31 Finding Her Voice Through Music 29:16 The Turning Point and Empowerment 32:44 Final Thoughts and Messages for the Audience DISCLAIMER:THE INFORMATION PROVIDED BY RENEE SWANSON, COVERT NARCISSISM PODCAST, AND CNG LIFE COACHING IS FOR EDUCATIONAL PURPOSES ONLY AND IS NOT TO BE USED FOR DIAGNOSIS PURPOSES AND NOT INTENDED TO BE A SUBSTITUTE FOR CLINICAL CARE. PLEASE CONSULT A HEALTH CARE PROVIDER FOR GUIDANCE SPECIFIC TO YOUR CASE. THIS MATERIAL DISCUSSES NARCISSISM IN GENERAL. RENEE SHARES STORIES FROM HER PERSONAL EXPERIENCES AS WELL AS FROM THOSE SHE HAS TALKED WITH FOR SEVERAL YEARS. HER MATERIAL DOES NOT CLAIM THAT ANY SPECIFIC PERSON HAS NARCISSISM AND SHOULD NOT BE USED TO REFER TO ANY SPECIFIC PERSON AS HAVING NARCISSISM. PERMISSION IS NOT GRANTED TO LINK TO OR REPOST THIS MATERIAL TO SUPPORT AN ALLEGATION OR SUPPORT A CLAIM THAT ANY SPECIFIC PERSON IS A NARCISSIST. THAT WOULD BE AN UNAUTHORIZED MISUSE OF THE MATERIAL AND INFORMATION PROVIDED. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

One of the most precious resources in dementia care are the stories we share. Today, we welcome back two deeply respected members of the Love Conquers Alz family for a conversation rooted in care, credibility, and shared purpose that has led to a major milestone:Marianne Sciucco, registered nurse, author, and  founding member of AlzAuthors, a groundbreaking global, rigorously vetted hub for Alzheimer's and dementia books, blogs, films, and podcasts, is passing the baton to senior care professional, writer Lance A. Slatton, host of the award-winning All Home Care Matters podcast and YouTube channel. , For over a decade, Marianne and the AlzAuthors team have thoughtfully spotlighted the most meaningful and reliable literature available for the Alzheimer's and dementia community. At a time when families are often overwhelmed by information, their careful curation created a trusted guidepost grounded in lived experience and compassion.Lance brings more than two decades of experience in senior care and continues to be a consistent, dependable voice, not only as a podcast host, but through his work as a Senior Case Manager with Enriched Life Home Care Services.What connects Marianne and Lance is presence. Both have remained steady voices in an ever-changing landscape, offering stringently curated, reliable resources to caregivers and families when clarity matters most.Join us as we celebrate a community that refuses to let its most valuable assets—truth, art, and love—fade into the noise. Subscribe, share with a caregiver who needs a lifeline, and tell us what resource you want to see next. Your voice shapes where this library goes from here.Support the showNo Country For Old People; a Nursing Home Exposé is STREAMING NOW on Amazon Prime (https://www.amazon.com/gp/video/detail/B0F7D1RR5X/ref=atv_dp_share_cu_r) Visit the No Country For Old People Website for more information. Please watch. Review. Share. Be a ROAR-ior!! JOIN THE R.O.A.R. MOVEMENT for quality long term care! Visit the ROAR 4 Long Term CareWebsite for more information.Follow us on Twitter, FB, IG, & TiK Tok

Tatyana Ali (Abbott Elementary, The Fresh Prince of Bel-Air) stars as a savvy starfish who outwits a wily whale in this tale from Aboriginal Australia. Sign up for our monthly newsletter, "The Lion's Roar", here.

CINCINNATI -- What are the lessons to be learned for the Bengals from the Patriots' run to the AFC Championship? What are the biggest takeaways from the Sean McDermott firing in Buffalo and what does it mean for Josh Allen? Where should the Bengals be focused on come the draft in April? Trags discusses all of it and much more with Alex Barth, Patriots reporter from 98.5 The Sports Hub in Boston. Learn more about your ad choices. Visit megaphone.fm/adchoices

Ready to take your community connection to the next level? This episode is for you if you've got a bit more budget, a bit more bandwidth, and you're looking for bold ways to make a big impact. In this final instalment of the Turning Culture Into Capital series, Stacey explores the high-time, high-investment strategies that build lasting visibility, loyalty, and brand momentum. From gala dinners to major fundraisers and sponsorships, these ideas are all about turning generosity into genuine growth—for your business and your community. You’ll learn: ✨ Why big events can pay off in big ways—when they align with your values and capacity✨ Real-life stories of Stacey’s $25K fundraising journey (and the ribs, rugby, and face paint that made it magic)✨ How to choose causes that matter to your team and your customers✨ The value of sponsoring vs. hosting—and why both can elevate your brand✨ How to avoid burnout by finding the right rhythm and capacity for your business✨ Why strategic community investment isn’t a “nice to have”—it’s a powerful business driver

The 2026 international signing period is underway. On "Days of Roar," Evan Petzold and Chris Brown react to the Detroit Tigers signing three international prospects to seven-figure bonuses: catcher Manuel Bolivar, shortstop Oscar Tineo and outfielder Randy Santana — and debate which teenage prospect has the best chance to develop into a special player. We discuss the remaining free agents who fit the Tigers' roster and payroll, such as starter Chris Bassitt and reliever Seranthony Domínguez, then answer a listener question: If the Tigers don't make another move, is the current roster good enough to reach the postseason in 2026? Ben Badler of Baseball America joins the show for a deep dive into the 2026 international class, evaluating the Tigers' top signings and explaining how the Tigers can gain an edge in the international market moving forward. He also provides an update on record-breaking signee Cris Rodriguez from the 2025 international class after his standout performance in the Dominican Summer League. There's more Tarik Skubal vs. Tigers discussion, as we try to figure out if the salary arbitration showdown is really just a Scott Harris vs. Scott Boras battle (or an owners vs. union battle) — and whether there's a path for both sides to walk away satisfied. Follow Evan on X/Twitter here. Read Evan's most recent work here

Her får du en smakebit av en annen podkast fra E24, Penger, pølser og politikk, som kommer hver mandag etter lunsj. Donald Trumps sult etter Grønland vil ikke gi seg. Vil EU svare på hans nye trusler med å trekke frem handelsbazookaen? Dette vil uansett bli en uke som kan være avgjørende for det fremtidige samarbeidet mellom USA og Europa. Roar tipper fotball-VM nå henger i en tynn tråd. Denne uken vil også handle om sjøfly, jakt og fiske når rettssaken mot tidligere leder for Norsk Industri, Stein Lier-Hansen, starter i Oslo Tingrett.

Tom talks about his move, DJ talks about Roar, then they jump into some good questions provided by some podcast listenersDiscord LinkShow your lizard brains on the outside with Merch!CLICK HERE FOR THE MERCHYoutube LinkSpicy Cat Racing Store

On this episode of Going Ringside we look back at one of the most incredible spectacles in pro wrestling history that occurred all over Everbank Stadium. In 2020 Jacksonville-based All Elite Wrestling (AEW) put on a 10-man tag team match they dubbed “Stadium Stampede”. We interview AEW Star Sammy Guevara who was in the brutal match that even involved the Jaguars mascot Jaxson de Ville and the Roar of the Jaguars. We also interview NXT star Sol Ruca right afterward on this same episode. Learn more about your ad choices. Visit megaphone.fm/adchoices

Free Resource: Feral Female's Content + Sales Simplification Crash Course: https://www.karrieoutloud.com/content-simplification-crash-course

Jeff Meacham (Black-ish, Vampirina) plays a hapless hero whose life turns upside-down in this humorous tale from Great Britain, Italy, Russia and the Philippines. Sign up for our monthly newsletter, "The Lion's Roar", here.

You don’t need a massive marketing budget or a whole team to make a meaningful impact in your community. You just need intention, alignment, and a few smart strategies. In this episode, Stacey continues the Turning Culture Into Capital series by breaking down low-budget, high-impact ways to get visible, build relationships, and contribute to your community—without burning yourself out (or breaking the bank). You’ll learn: ✨ The best low-budget, low-time ideas (hint: T-shirt sponsorships and raffle donations still go a long way)✨ Creative low-budget, high-time opportunities to grow your presence and influence—from joining a local board to hosting networking events✨ Why your contributions don’t always need to be flashy—they just need to be intentional✨ Real talk on choosing opportunities that align with your strengths (not your nightmares)✨ How awards, volunteering, and showing up locally can skyrocket your brand credibility Whether you’ve got $20 or two hours to spare, this episode will help you find a starting point that feels aligned and sustainable—so you can start building real community capital your way.

The Tarik Skubal-Detroit Tigers showdown is officially underway. The Tigers and the back-to-back American League Cy Young winner failed to reach an agreement before the arbitration deadline, filing $13 million apart: the Tigers at $19 million; Skubal at $32 million — setting up the most significant arbitration hearing in MLB history. On "Days of Roar," Evan Petzold and Chris Brown react to the massive gap, explain the importance of the $25.5 million midpoint and debate about who will win the case. We also discuss Alex Bregman signing with the Chicago Cubs — and what it means for the Tigers at third base. Evan Drellich, senior writer for The Athletic, joins the show for an in-depth interview about his expertise: labor and business in baseball. He breaks down Skubal's unprecedented arbitration case and impending free agency, looming collective bargaining agreement tensions, the possibility of another lockout and the collapse of regional sports networks. Follow Evan on X/Twitter here. Read Evan's most recent work here

From Scott McTominay heroics in 4 goal thriller as Napoli draw Inter Milan, Christian Pulisic and Marco Brescianini misfire as AC Milan and Fiorentina share points, Matias Soulé the architect behind Roma win, to Como unable to capitalize on advantage against 10 men Bologna as Martin Baturina scores a rocket, Charles De Ketelaere continues to shine for Atalanta, Matteo Tramoni wondergoal as Pisa and Udinese draw, and Lecce meltdown against Parma, Lazio beat Hellas Verona after VAR controversy, as well as this week's Baggio, Serie ASS and Premface of the week plus much, much more when Nima and Carlo break down all the main talking points from Match Day 19 of the 2025/2026 Serie A season. Timestamps: 00:00 Intro - Match Day 19 Episode Overview 02:01 Discussion On Daniele Doveri & The VAR Calls 12:51 Inter Milan - Big Match Curse Lives On As Federico Dimarco Continues To Shine 24:57 Napoli - Scott McTominay Already A Club Legend After Only 18 Months 36:11 AC Milan - Christian Pulisic Misfires When Max Allegri Rotates 48:52 Fiorentina - Important Point Won But Marco Brescianini Miss Costs The Win 50:46 Roma - Matias Soulé & Manu Koné Lead Strong 2nd Half Showing 55:57 Como vs Bologna - Martin Baturina Rocket Salvages Point As Nicolò Cambiaghi Loses Head 57:48 Atalanta - Charles De Ketelaere Stars As La Dea Record 9th Win In Last 11 01:00:05 Best Of The Rest - Lecce Red Card Meltdown Against Parma, Matteo Tramoni Wondergoal As Pisa Draw Udinese and Lazio Beat Hellas Verona After VAR Controversy 01:05:50 Baggio, Premface & Serie ASS Of The Week If you want to support The Italian Football Podcast and get every episode, simply become a member on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon.com/TIFP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ OR ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ OR ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Memberships⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Your support makes The Italian Football Podcast possible.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok Learn more about your ad choices. Visit podcastchoices.com/adchoices

Shaun Cassidy is a true creative multi-hyphenate whose career spans music, television, theater, and storytelling. First rising to fame as one of the biggest teen idols of the late 1970s, Shaun signed with Warner Brothers Records while still in high school, released three multi-platinum albums, earned a Grammy nomination, and performed in sold-out venues like Madison Square Garden and the Houston Astrodome — all while starring in the iconic ABC series The Hardy Boys Mysteries. Behind the scenes, Shaun quietly reinvented himself as one of television's most respected writers and producers. His work includes creating and producing critically acclaimed series such as American Gothic, Roar, Cold Case, The Agency, Invasion, Emerald City, and New Amsterdam, which completed a powerful five-year run on NBC and Netflix. In this conversation, Shaun reflects on the courage it takes to evolve beyond early success, what reinvention really looks like over a multi-decade career, and why creativity has no expiration date. He also opens up about returning to live performance in 2020 with his one-man show The Magic of a Midnight Sky, the grounding role family has played in his life, and what legacy means to him now. This episode is an honest, thoughtful look at reinvention, purpose, and the power of staying connected to who you're becoming. In this episode, we talk about: • Rising to fame as a teen idol and navigating success at a young age • Balancing music, television, and public life simultaneously • Reinventing a career behind the scenes as a writer and producer • The creative leap from performer to storyteller • Why compassion-driven stories resonate so deeply today • Returning to live performance after nearly 40 years • The role family plays in grounding long-term success • Redefining purpose and legacy beyond career milestones • Why it's never too late to begin again creatively Connect with Shaun Cassidy: Official website https://www.shauncassidy.com Instagram https://www.instagram.com/shauncassidyofficial Learn more about New Amsterdam https://www.nbc.com/new-amsterdam

A Monologue. The iRacing Daytona ROAR/Prelude Weekend, into the Virtual Daytona 24, into the IMSA Daytona 24.

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

Her får du en smakebit av en annen podkast fra E24, Penger, pølser og politikk, som kommer hver mandag etter lunsj. Trump har bestemt seg for å etterforske den amerikanske sentralbanksjefen Jerome Powell, angivelig for en kostbar oppussing av sentralbankbygningene i Washington DC. Roar mener at kostnadsoverskridelsene det er snakk om kun er peanøtter sett med norske øyne, mer alvorlig er det hvordan granskningen truer uavhengigheten til den amerikanske sentralbanken og pengepolitikken der borte. Det blir mye Trump i denne episoden, for vi må også følge med på hva som skjer i Iran denne uken og om USA velger å blande seg i det som skjer der.

CINCINNATI -- Bengals director of player personnel Duke Tobin spent 63 minutes Friday answering questions from reporters about the failures of the 2025 Bengals and why he believes he, his staff and Zac Taylor deserve another chance to turn it around in 2026. Trags and Skinny break down all the major takeaways from Friday's unusual presser. Learn more about your ad choices. Visit megaphone.fm/adchoices

Conference play is in full swing and so is college basketball! Football is slowly dwindling and our sport is poised to take center stage. The Weave catch you up on the past week! The Rundown: (0:00) Intro  (3:10) Root's Roundup  (10:05) Weave Saw That  (37:25) Three Man Thoughts  (1:03:35) Game Previews (1:09:45) Reviews  Join Basket Under Review for access to deep dives, player rankings, team previews, Trilly Donovan's Discord, and more! https://www.basketunderreview.com/ Homefield Apparel: https://www.homefieldapparel.com CBB Analytics: https://cbbanalytics.com/

Taylor Richardson (The Gilded Age) and Alison Wright (The Americans, Snowpiercer) co-star in this Irish tale about mischievous fairies and the power of music. Sign up for our monthly newsletter, "The Lion's Roar", here.

Midlife fitness for women 45+ is not about trying harder—it's about training smarter for perimenopause and menopause physiology. In this powerhouse episode of Asking for a Friend, host Michele Folan sits down with Dr. Stacy Sims—exercise physiologist, TEDx speaker behind “Women Are Not Small Men,” and author of ROAR and Next Level—to break down exactly why your old workouts and “eat less, do more cardio” strategies stop working in midlife… and what to do instead.We get practical (and refreshingly no-BS) about the real midlife playbook:Why estrogen shifts change metabolism, muscle power, recovery, and body compositionWhy heavy lifting matters (and why it won't make you “bulky”)The difference between HIIT vs. Sprint Interval Training (SIT)—and why many “HIIT classes” aren't actually HIITWhere Zone 2 fits (and why it's great for mental health, but not your best lever for optimization)The truth about fasted workouts and intermittent fasting for women—and how it can backfire on appetite, cravings, energy, and sleepHow to think about protein needs in midlife (including the “1 gram per pound” conversation and how to distribute it)Why creatine is having a moment (brain, muscle, mood, performance, and aging)—and what dosing typically looks likeRecovery upgrades in perimenopause/menopause: sleep, mobility, heat/sauna (and why cold plunge isn't a one-size-fits-all tool for women)Why testing and metrics like DEXA (bone density + body comp) and VO2 max can be useful for longevity-focused womenIf you've been standing in your kitchen wondering where your “30-year-old metabolism” went—and why you can't out-discipline midlife hormones—this episode will give you clarity, strategy, and a realistic path forward.You can find her newsletter and blog at: https://www.drstacysims.com/ You can receive 15% off her online courses at https://www.drstacysims.com/product_guide using the code DRSTACYSIMS15OFFhttps://www.instagram.com/drstacysimshttps://www.youtube.com/channel/UCPD55VPa1ZWx1a_nzWC2VJA_________________________________________1:1 health and nutrition coaching or Faster Way - Reach me anytime at mailto:mfolanfasterway@gmail.com If you're doing “all the right things” and still feel stuck, it may be time to look deeper. I've partnered with EllieMD, a trusted telehealth platform offering modern solutions for women in midlife—including micro-dosed GLP-1 peptide therapy—to support metabolic health and longevity. https://elliemd.com/michelefolan - Create a free account to view all products. ✨ Sign up for my weekly newsletter: https://michelefolanfasterway.myflodesk.com/i6i44jw4fq

Tony Newgrosh hosts this week and is joined by David Blakeney, Julian Bloom and Nick Goldstone. ⁠⁠⁠citypodcast.net⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@citypodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Produced by Paul Myers and Mike Leigh  Engineered by Leon Gorman  A Playback Media Production  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠playbackmedia.co.uk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Copyright 2025 Playback Media Ltd - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠playbackmedia.co.uk/copyright Learn more about your ad choices. Visit podcastchoices.com/adchoices

You’re already doing great things in your business—but are people seeing it? In this episode, Stacey continues the Turning Culture Into Capital series with a strategic (and deeply encouraging) look at how to make your community engagement visible—so your investment of time, money, and energy doesn’t go unnoticed. Because giving back isn’t just a feel-good bonus. When done well, it’s a business growth strategy that attracts loyal customers, dream team members, and powerful brand awareness. You’ll learn: ✨ How to make sure your community contributions are seen, celebrated, and shared✨ The ROI of visibility—why your fruit shop loyalty might be all about more than just apples✨ Smart ways to build brand awareness through sponsorships, local media, and partnerships✨ How to delegate visibility (hint: promote your most outgoing team member!)✨ Why alignment, not obligation, should drive your community involvement✨ What to avoid when choosing where and how to give back (including that 3am regret shift!) Plus, Stacey shares real stories from her own business and clients—reminding you that when you're strategic and values-aligned, your community investment won’t just feel good… it’ll pay off.

In this holiday edition of "Days of Roar," Evan Petzold and Chris Brown dive into the latest news about the Detroit Tigers, including more pitchers being signed to minor-league contracts — and why outfielder Randal Grichuk could be a good fit for the Tigers as a Jahmai Jones backup plan, as long as he's willing to sign a minor-league deal. In the Big 2, Evan and Chris outline their New Year's resolutions for the Tigers in the 2026 calendar year: sign George Springer, extend Kevin McGonigle, prepare for life after Tarik Skubal, find a true No. 2 starter, create stability on the left side of the infield and make a splash via free agency or trade. Los Angeles Angels beat writer Jeff Fletcher, from the Orange County Register, joins the show to share insight about new Tigers reliever Kenley Jansen, providing key information about his presence in the clubhouse as a leader and a personal reason for why his underlying metrics dipped last season. To wrap up, Chris shares six under-the-radar prospects who could break out in 2026: John Peck, Jackson Strong, Angel De Los Santos, Kelvis Salcedo, Cale Wetwiska and Jhonan Coba. Follow Evan on X/Twitter here. Read Evan's most recent work here

Dr. Lisa Cooney is a world renowned authority on thriving after trauma, be it physical, emotional, sexual or financial. Over the past 25 years she's supported thousands of clients to break free from abuse and any form of limitation so they can create a life they truly enjoy. She is a Licensed Marriage and Family Therapist, Master ThetaHealer, Certified Access Consciousness® Facilitator and 3-Day Body Class Facilitator®. She is also the creator of the ROAR® (Radically Orgasmic Alive Reality) Method. This cutting edge approach to transformation is based on practices she used to heal herself from early childhood abuse and a life-threatening disease. Now she trains and certifies practitioners worldwide to use and facilitate the ROAR Method®. A maverick of consciousness, Dr. Lisa weaves together an eclectic blend of cross-cultural, multi-faith, collaborative and participatory spiritual approaches in her work with people. She is a catalyst for change, dedicated to assisting others to acknowledge their true power, courage and unique purpose. All of Dr. Lisa's classes, both in person and online, are dynamic and different yet also have something in common: they're fun, life-changing and full of pragmatic tools that allow people to actualize the lives they always dreamed of yet didn't dare hope to have. She's known for encouraging people to, "Be You! Beyond Anything! Create Magic! Live your ROAR™!" and to be their own best friend. A bestselling author, she's written three books, Radically Alive Beyond Abuse, Lies of Money, and Creating After Abuse and is a contributing author to several books, including The Energy of Healing and The Energy of Creativity. Dr. Lisa is deeply passionate about inspiring and motivating people to choose greater and allow a life of ease, joy and fun. She is also strongly moved to bridge global discrepancies of conflict and violence through tangible, kind and caring forms of conscious, mindful communication and conversations. Something you may not know about Dr. Lisa is that she's a licensed gun owner and is a great shot! She lives in Dallas, Texas, with Bella, her adorable French bulldog.  Connect with Jon Dwoskin: Twitter: @jdwoskin Facebook: https://www.facebook.com/jonathan.dwoskin Instagram: https://www.instagram.com/thejondwoskinexperience/ Website: https://jondwoskin.com/LinkedIn: https://www.linkedin.com/in/jondwoskin/ Email: jon@jondwoskin.com Get Jon's Book: The Think Big Movement: Grow your business big. Very Big!   Connect with Dr. Lisa Cooney:Website: https://www.drlisacooney.com/ Facebook: https://www.facebook.com/drlisacooney Twitter: https://twitter.com/DrLisaCooney Instagram: https://www.instagram.com/drlisacooney/ YouTube: https://www.youtube.com/channel/UCS4dP_x2Y8XXMiNuTTyxk8g Pinterest: https://www.pinterest.com/drlisacooney LinkedIn: https://www.linkedin.com/in/dr-lisa-cooney-8215b1203/                                                                                     *E – explicit language may be used in this podcast.

CINCINNATI -- The Bengals outplayed their in-state rivals for most of the game but two defensive touchdowns by Cleveland and a last-second 49-yard field goal by Andre Szmyt spelled doom for the Bengals in a 20-18 Cleveland win Sunday at Paycor Stadium. Joe Burrow and Ja'Marr Chase has pointed comments postgame about what should be next in the offseason for the Bengals, which starts Monday with exit interviews. Will it matter in Cincinnati in 2026? Trags and Skinny with the post-mortem. Learn more about your ad choices. Visit megaphone.fm/adchoices

TIME TO CHANGE THE WORLD LADIES

Shannon Salter shares what happened when her family offered confessions at her father's wake.

Liz and Sarah are continuing their tradition of Roar ‘24 and Hive ‘25 with ChexMix ‘26. In a few days, they’ll spend the night at the Emerald Iguana Inn in Ojai and plot the next year of their career. Also? They’ll drink wine. In Take A Hike, they each share a new practice for 2026. Inspired by the book I Remember by Joe Brainard, Liz is going to record memories about her beloved dad. Sarah is going to roast a chicken every week — and use items from her own garden to season it! Next, in Take Two, Sarah shares what she’s learned about her algorithm after their recent Alter Your Algorithm Challenge. This week’s Hollywood Hack is pure whimsy: Hinge Heads. Finally Liz recommends the new season of Vanderpump Rules on Bravo. Sign up for Liz & Sarah’s free weekly Substack newsletter at https://happierinhollywoodpod.substack.com. It will come right to your inbox! Get in touch on Instagram: @Sfain & @LizCraft Get in touch on Threads: @Sfain & @LizCra Visit our website: https://happierinhollywood.com Join our Facebook group: https://www.facebook.com/HappierinHollywood/ Happier in Hollywood is part of ‘The Onward Project,’ a family of podcasts brought together by Gretchen Rubin—all about how to make your life better. Check out the other Onward Project podcasts—Happier with Gretchen Rubin, and Side Hustle School . If you liked this episode, please subscribe, leave a review, and tell your friends! LINKS: Emerald Iguana Inn: https://www.emeraldiguana.com/ I Remember by Joe Brainard: https://amzn.to/3MRFL8Q Julie & Julia: My Year of Cooking Dangerously by Julie Powell: https://amzn.to/4j7q61a Unraveling by Peggy Orenstein: https://amzn.to/3MLnyKd Hinge Heads: Mushrooms: https://amzn.to/4pXnwh4 Chickens:https://amzn.to/4983t8c Cats:https://amzn.to/4qr0HSM Vanderpump Rules Season 12 trailer: https://www.youtube.com/shorts/oKgvwAFpHTESee omnystudio.com/listener for privacy information.

NPR's Peter Sagal (Wait, Wait... Don't Tell Me!) stars in this Russian story about how fantastically priceless a little generosity can be. Sign up for our monthly newsletter, "The Lion's Roar", here.

It's a special collab episode! Chelsea and What Went Wrong hosts Lizzie Bassett and Chris Winterbauer dive into chaotic movie-making stories hidden inside celebrity memoirs and behind-the-scenes Hollywood tea. They trade wild anecdotes, including Tippi Hedren filming with real lions on “Roar,” Barbra Streisand's blunt take on “A Star Is Born” remakes, Jennifer Grey's mid-shoot plastic surgery, Elizabeth Taylor trading lovers while making “Cleopatra,” Rob Lowe's fight club with Tom Cruise, and so much more. Find the full list of books and resources recommended in this episode AND learn more about writing and creating by checking out The Behind the Bangs Patreon. Where to find our guests:  What Went Wrong on Apple Podcasts What Went Wrong on Spotify What Went Wrong Patreon What Went Wrong on Instagram Lizzie Bassett:  Instagram *** Glamorous Trash is all about going high and low at the same time— Glam and Trash. We recap and book club celebrity memoirs, deconstruct pop culture, and sometimes, we cry! If you've ever referenced Mariah Carey in therapy... then this is the podcast for you. Thank you to our sponsors: Quince  - Go to quince.com/glamorous for free shipping on your order and 365-day returns.  Thrive Causemetics - Get 20% off your first order at thrivecausemetics.com/glamorous Libro.fm - Click here to get 2 audiobooks for the price of 1 with your first month of membership using code TRASH. Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode of Currently Reading, Kaytee and Meredith are taking a look back at their favorite reads of 2021. This was one of the best reading years. This was also the year we added the superlatives which everybody loved! Most of these books should be available for you to grab if any interest you after hearing us rave about them! Show notes are time-stamped below for your convenience. Read the transcript of the episode (this link only works on the main site) .  .  .  2:38 - Our Top 10 Reads of 2021 12:35 - Legendborn by Tracy Deonn (Kaytee #10) 12:39 - Season 3: episode 40 14:09 - Currently Reading Patreon 16:39 - Fablehaven by Brandon Mull  16:52 - A Place to Hang the Moon by Kate Albus (Meredith #10) 18:50 - The Love Hypothesis by Ali Hazelwood (Kaytee #9) 21:25 - Furyborn by Claire Legrand 21:36 - Shadow and Bone by Leigh Bardugo  21:56 - A Court of Wings and Ruin by Sarah J. Maas (Meredith #9) 22:21 - A Court of Mist and Fury by Sarah J. Maas 23:01 - A Court of Thorns and Roses by Sarah J. Maas 23:46 - The Day The World Came to Town by Jim DeFede (Kaytee #8) 23:50 - Season 4: Episode 14 25:32 - Wintering: The Power of Rest and Retreat in Difficult Times by Katherine May (Meredith #8) 25:41 - Season 3: Episode 41 29:03 - Project Hail Mary by Andy Weir (Kaytee #7) 29:25 - Season 3: Episode 42 31:41 - State of Terror by Hilary Rodham Clinton and Louise Penny (Meredith #7) 34:22 - Intermission: Lowest Rated Books 34:58 - Roar by Cecilia Ahern (Kaytee) 35:41 - Atomic City Girls by Janet Beard (Kaytee) 36:48 - Survivor Song by Paul Tremblay (Meredith) 37:30 - Survive the Night by Riley Sager (Meredith) 38:25 - Meredith and Kaytee's Top 10 Books of the Year cont'd 38:36 - Love Lives Here by Rowan Jette Knox (Kaytee #6) K NOTE: while I do think it's clear that I love my sister dearly here, I want to be extra super clear that when I say "love covers all manner of sins" I am referring to the ways we as her family fail at times to do the best we can. I am not in any way referring to her gender identity as a sin. My sister knows this, but I want to be sure that anyone else who hears me, hears me correctly as well. 40:25 - Pony by R.J. Palacio (Meredith #6) 40:50 - Page & Palette Bookshop 42:05 - Wonder by R.J. Palacio 43:01 - The Guncle by Steven Rowley (Kaytee #5) 43:04 - Season 3: Episode 45 44:29 - The Devotion of Suspect X by Keigo Higashino (Meredith #5) 47:46 - Amari and the Night Brothers by B.B. Alston (Kaytee #4) 47:51 - Season 3: Episode 35 47:56 - Bookshelf Thomasville 48:47 - Blackwell's 49:05 - Nevermoor by Jessica Townsend 49:06 - Harry Potter and the Sorcerer's Stone by J.K. Rowling 49:28 - 56 Days by Catherine Ryan Howard  49:37 - The Nothing Man by Catherine Ryan Howard (Meredith #4) 53:14 - Intermission: The Books that Surprised Us Most in 2021 53:44 - Season 3: Episode 34 53:50 - The Black Count by Tom Reiss (Kaytee) 55:38 - Piranesi by Susanna Clarke (Meredith) 59:25 - Meredith and Kaytee's Top 10 Books of the Year cont'd 59:50 - How the Word is Passed by Clint Smith (Kaytee #3) 59:56 - Season 4: Episode 19 1:01:37 - Fabled Bookshop 1:01:39 - We Begin at the End by Chris Whitaker (Meredith #3) 1:04:52 - Razorblade Tears by S.A. Cosby (Kaytee #2) 1:04:56 - Season 4: Episode 2 1:07:18 - Matrix by Lauren Groff (Meredith #2) 1:07:59 - Fates and Furies by Lauren Groff 1:11:14 - All The Lonely People by Mike Gayle (Kaytee #1) 1:11:22 - Season 4: Episode 12 1:11:38 - Minisode w/Mike Gayle 1:14:09 - A Gentleman in Moscow by Amor Towles (Meredith #1) 1:15:42 - The Count of Monte Cristo by Alexandre Dumas 1:22:48 - Reflections from the 2021 Reading Year 1:24:25 - Pony by R.J. Palacio 1:24:45 - Amari and the Night Brothers by B.B. Alston   Support Us: Become a Bookish Friend | Grab Some Merch Shop Bookshop dot org | Shop Amazon Bookish Friends Receive: The Indie Press List with a curated list of five books hand sold by the indie of the month. December's IPL is a recap of the year with Kaytee and Meredith. Love and Chili Peppers with Kaytee and Rebekah - romance lovers get their due with this special episode focused entirely on the best selling genre fiction in the business.  All Things Murderful with Meredith and Elizabeth - special content for the scary-lovers, brought to you with the behind-the-scenes insights of an independent bookseller From the Editor's Desk with Kaytee and Bunmi Ishola - a quarterly peek behind the curtain at the publishing industry The Bookish Friends Facebook Group - where you can build community with bookish friends from around the globe as well as our hosts Connect With Us: The Show: Instagram | Website | Email | Threads The Hosts and Regulars: Meredith | Kaytee | Mary | Roxanna Production and Editing: Megan Phouthavong Evans Affiliate Disclosure: All affiliate links go to Bookshop unless otherwise noted. Shopping here helps keep the lights on and benefits indie bookstores. Thanks for your support!

This episode originally released on March 11, 2024. While Don and I are taking a much needed break, we wanted to share one of our most popular and valuable episodes in case you missed it. And if you already heard it, it couldn't hurt to listen again because the episode is filled with powerful informstion for keeping your brain as healthy as you possibly can! Have a happy and healthy 2026...and thank you all for listening! Don and I both agree that this episode ranks as one of our favorites to date. Our amazing guest, Dr. Mitchell Clionsky is a board certified neuropsychologist with more than 30 years of clinical experience and has treated more than 20,000 patients with cognitive problems. Dr. Clionsky understands the toll of memory disorders as both a caring professional and as the son of his mother Muriel, who died in 2008 from dementia. Dr. Clionsky holds staff privileges on four hospitals and in addition to dementia, he evaluates ADHD, concussions, and a variety of neurological conditions. From years of patient data, Dr. Clionsky and his wife/partner Emily Clionsky, MD have developed the Memory Orientation Screening Test or MOST, a highly valid measure that provides a single, numerical score that reflects cognitive status and change over time. MOST helps identify -cognitive problems- earlier in the deterioration process so health professionals can intervene and help their patients live better lives.Now Dr. Clionsky and his wife, Emily, have taken what they do in their consulting room and have written a new book, Dementia Prevention: Using Your Head to Save Your Brain. It's an exciting, fun to read, motivating, and potentially life changing read that is the culmination of 45 years of extensive clinical evaluation and treatment. Scientifically detailed and vetted by Johns Hopkins University doctors and content experts, it is translated into terms that almost everyone will understand.8 out of 10 people over 55 say that Alzheimer's disease and other dementias are a major concern. Well now there is something that can be done. Dementia is not inevitable, but for 1 out of 2 people it is preventable. And we are so excited to share all about this fascinating breakthrough. Enjoy!!Connect with Dr. Clionsky here.Support the showNo Country For Old People; a Nursing Home Exposé is STREAMING NOW on Amazon Prime (https://www.amazon.com/gp/video/detail/B0F7D1RR5X/ref=atv_dp_share_cu_r) Visit the No Country For Old People Website for more information. Please watch. Review. Share. Be a ROAR-ior!! JOIN THE R.O.A.R. MOVEMENT for quality long term care! Visit the ROAR 4 Long Term CareWebsite for more information.Follow us on Twitter, FB, IG, & TiK Tok

Jim Zug, the preeminent historian of Squash in the US, joins Squash Radio to discuss  releasing the updated version of "Squash, a History of the Game".  Jim & Bill reminisce about their time as colleagues at US Squash, including launching the 'Outside the Glass" podcast, editing Squash Magazine, and the USQ Hall of Fame. Jim also offers his perspective on college squash and the greatest all-time American PSA players. Squash Radio is sponsored by Sunrise Courts: www.sunrise-courts.com & Penfold Golf: www.penfoldgoffusa.com.

Kennedy Kanagawa (Into The Woods) plays a young man who brings light to a dark world in this tale with roots in Alaska Native and First Nations legends. Sign up for our monthly newsletter, "The Lion's Roar", here.

Gabe Kunda (Marvel Rivals, Apex Legends) and Natasha Rothwell (The White Lotus, Insecure) co-star in a Ugandan legend about friendship, rivalry, and making music. Sign up for our monthly newsletter, "The Lion's Roar", here.

Ravi V. Patel (Animal Control, LEGO Masters Jr.) headlines this Indian tale about distinguishing need from greed with help from grain, gold, and a barrel of lies. Sign up for our monthly newsletter, "The Lion's Roar", here.